(−)‐Phenserine tartrate (PhenT) as a treatment for traumatic brain injury
Open Access
- 11 December 2019
- journal article
- research article
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 26 (6) , 636-649
Abstract
Aim: Traumatic brain injury (TBI) is one of the most common causes of morbidity and mortality of both young adults and the elderly, and is a key contributing factor in about 30% of all injury‐associated deaths occurring within the United States of America. Albeit substantial impact has been made to improve our comprehension of the mechanisms that underpin the primary and secondary injury stages initiated by a TBI incident, this knowledge has yet to successfully translate into the development of an effective TBI pharmacological treatment. Developing consent suggests that a TBI can concomitantly trigger multiple TBI‐linked cascades that then progress in parallel and, if correct, the multifactorial nature of TBI would make the discovery of a single effective mechanism‐targeted drug unlikely.Discussion: We review recent data indicating that the small molecular weight drug (−)‐phenserine tartrate (PhenT), originally developed for Alzheimer's disease (AD), effectively inhibits a broad range of mechanisms pertinent to mild (m) and moderate (mod)TBI, which in combination underpin the ensuing cognitive and motor impairments. In cellular and animal models at clinically translatable doses, PhenT mitigated mTBI‐ and modTBI‐induced programmed neuronal cell death (PNCD), oxidative stress, glutamate excitotoxicity, neuroinflammation, and effectively reversed injury‐induced gene pathways leading to chronic neurodegeneration. In addition to proving efficacious in well‐characterized animal TBI models, significantly mitigating cognitive and motor impairments, the drug also has demonstrated neuroprotective actions against ischemic stroke and the organophosphorus nerve agent and chemical weapon, soman.Conclusion: In the light of its tolerability in AD clinical trials, PhenT is an agent that can be fast‐tracked for evaluation in not only civilian TBI, but also as a potentially protective agent in battlefield conditions where TBI and chemical weapon exposure are increasingly jointly occurring.Keywords
Funding Information
- Ministry of Science and Technology, Taiwan (MOST104‐2923‐B‐038‐001‐MY3 and MOST108-2321-B-038-008)
- National Institutes of Health (R56 AG057028)
This publication has 73 references indexed in Scilit:
- Returning Service Members to Duty Following Mild Traumatic Brain Injury: Exploring the Use of Dual-Task and Multitask Assessment MethodsPhysical Therapy, 2013
- Neurotrophic and Neuroprotective Actions of (−)- and (+)-Phenserine, Candidate Drugs for Alzheimer’s DiseasePLOS ONE, 2013
- Molecular mechanisms of cognitive dysfunction following traumatic brain injuryFrontiers in Aging Neuroscience, 2013
- Animal modelling of traumatic brain injury in preclinical drug development: where do we go from here?British Journal of Pharmacology, 2011
- Repeat traumatic brain injury in the developing brainInternational Journal of Developmental Neuroscience, 2011
- Delayed reduction in hippocampal postsynaptic density protein-95 expression temporally correlates with cognitive dysfunction following controlled cortical impact in miceJournal of Neurosurgery, 2010
- Modulation of human neural stem cell differentiation in Alzheimer (APP23) transgenic mice by phenserineProceedings of the National Academy of Sciences, 2007
- The Experimental Alzheimer’s Disease Drug Posiphen [(+)-Phenserine] Lowers Amyloid-β Peptide Levels in Cell Culture and MiceThe Journal of Pharmacology and Experimental Therapeutics, 2007
- A systematic review of brain injury epidemiology in EuropeActa Neurochirurgica, 2005
- Long-term potentiation and memoryPhilosophical Transactions of the Royal Society B: Biological Sciences, 2003